The Role Of Maintenance Therapy In Gynecologic Cancer Treatment

By Rupa Doshi, Irene Figari and Mary Gunn

Advanced ovarian and endometrial carcinomas present the greatest challenge in treating gynecologic cancer and, among the five types of female cancers, are responsible for the most U.S. deaths annually.¹ With a combination of surgery, chemotherapy, and radiation; patients can go into remission, but the majority will have a recurrence after several months or years. There is a critical unmet need for better maintenance therapies to improve the quality of life and, ideally, achieve improvement in progression-free and overall survival for these women. Research has identified several useful specific agents, and biomarkers can help guide the selection of patients for maintenance therapy treatment.